Xvivo Perfusion AB (3XV) Stock Statistics & Valuation Metrics
Total Valuation
Xvivo Perfusion AB has a market cap or net worth of EUR 561.48M. The enterprise value is EUR 6.74B.
- Market Cap
- EUR 561.48M
- Enterprise Value
- EUR 6.74B
Share Statistics
Xvivo Perfusion AB has 31,499,470 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 31,499,470
- Owned by Insiders
- ―
- Owned by Institutions
- 8.04%
Financial Efficiency
Xvivo Perfusion AB’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 2.68%.
- Return on Equity (ROE)
- 0.01
- Return on Assets (ROA)
- 0.01
- Return on Invested Capital (ROIC)
- 2.68%
- Return on Capital Employed (ROCE)
- 0.04
- Revenue Per Employee
- 3.92M
- Profits Per Employee
- 121.56K
- Employee Count
- 207
- Asset Turnover
- 0.34
- Inventory Turnover
- 1.12
Valuation Ratios
The current PE Ratio of Xvivo Perfusion AB is 49.14. Xvivo Perfusion AB’s PEG ratio is 0.15.
- PE Ratio
- 49.14
- PS Ratio
- 6.60
- PB Ratio
- 2.79
- Price to FCF
- 33.05
- Price to Operating Cash Flow
- 23.56
- PEG Ratio
- 0.15
Income Statement
In the last 12 months, Xvivo Perfusion AB had revenue of 812.16M and earned 25.16M in profits. Earnings per share was 0.80.
- Revenue
- 812.16M
- Gross Profit
- 533.50M
- Operating Income
- 93.02M
- Pretax Income
- 38.56M
- Net Income
- 25.16M
- EBITDA
- 153.14M
- Earnings Per Share (EPS)
- 0.80
Cash Flow
In the last 12 months, operating cash flow was 268.77M and capital expenditures -164.14M, giving a free cash flow of 191.56M billion.
- Operating Cash Flow
- 268.77M
- Free Cash Flow
- 191.56M
- Free Cash Flow per Share
- 6.08
Dividends & Yields
Xvivo Perfusion AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.03%
- Earnings Yield
- 2.04%
Stock Price Statistics
- Beta
- 1.05
- 52-Week Price Change
- 4.46%
- 50-Day Moving Average
- 21.17
- 200-Day Moving Average
- 22.23
- Relative Strength Index (RSI)
- 38.28
- Average Volume (3m)
- 89
Important Dates
Xvivo Perfusion AB upcoming earnings date is Jan 28, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Oct 22, 2026
- Next Earnings Date
- Jan 28, 2027
- Ex-Dividend Date
- ―
Financial Position
Xvivo Perfusion AB as a current ratio of 5.77, with Debt / Equity ratio of 5.90%
- Current Ratio
- 5.77
- Quick Ratio
- 3.68
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.09
- Interest Coverage Ratio
- 2.10
Taxes
In the past 12 months, Xvivo Perfusion AB has paid 13.40M in taxes.
- Income Tax
- 13.40M
- Effective Tax Rate
- 0.35
Enterprise Valuation
Xvivo Perfusion AB EV to EBITDA ratio is 28.67, with an EV/FCF ratio of 32.05.
- EV to Sales
- 6.40
- EV to EBITDA
- 28.67
- EV to Free Cash Flow
- 32.05
- EV to Operating Cash Flow
- 22.84
Balance Sheet
Xvivo Perfusion AB has EUR 313.24M in cash and marketable securities with EUR 120.61M in debt, giving a net cash position of EUR 192.63M billion.
- Cash & Marketable Securities
- EUR 313.24M
- Total Debt
- EUR 120.61M
- Net Cash
- EUR 192.63M
- Net Cash Per Share
- EUR 6.12
- Tangible Book Value Per Share
- EUR 20.96
Margins
Gross margin is 64.09%, with operating margin of 12.83%, and net profit margin of 13.44%.
- Gross Margin
- 64.09%
- Operating Margin
- 12.83%
- Pretax Margin
- 16.23%
- Net Profit Margin
- 13.44%
- EBITDA Margin
- 22.33%
- EBIT Margin
- 12.84%
Analyst Forecast
The average price target for Xvivo Perfusion AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 21.17%
- EPS Growth Forecast
- 354.61%
